Loading organizations...
§ Private Profile · 1951 Northwest 7th Avenue, Miami, Florida, United States
Z-Quick Diagnostics is a company.
Key people at Z-Quick Diagnostics.
Z-Quick Diagnostics, LLC develops advanced diagnostic tools for emerging infectious diseases. The company focuses on highly specific detection methodologies, informed by understanding the adaptive immune system's T-cell and monoclonal antibody responses. These solutions identify critical pathogens like Coronaviruses, Zika, and HIV/SIV, leveraging immunological insights for urgent diagnostic needs.
Founded by Michael J. Ricciardi, in collaboration with his mentor Dr. David Watkins Ph.D., the company emerged from their extensive work on the adaptive immune system. Their insight centered on translating cutting-edge immunology into precise diagnostic solutions for public health threats. Ricciardi brings expertise in T-cells and monoclonal antibodies, complemented by Dr. Watkins's thirty years as a distinguished professor of infectious disease.
Z-Quick Diagnostics' products serve organizations and healthcare providers identifying and managing infectious disease outbreaks. The company's vision is to bolster global health security through rapid, precise detection capabilities for novel and re-emerging pathogens. It aims to remain at the forefront of diagnostic innovation, continuously evolving to meet future disease challenges.
Key people at Z-Quick Diagnostics.
Quest Diagnostics is the world's leading provider of diagnostic information services, offering a broad menu of over 3,500 routine, esoteric, and genetic tests to healthcare providers, patients, physicians, hospitals, and health systems across the United States, Puerto Rico, Mexico, and Brazil.[3][7] Headquartered in New Jersey as a Fortune 500 public company with nearly 50,000 employees, it serves 1 in 3 adult Americans and half of U.S. physicians and hospitals annually, holding a 13% market share in diagnostic and medical laboratories while generating about $9.25 billion in 2023 revenue.[1][3][7] The company solves critical healthcare challenges by delivering actionable diagnostic insights that empower better decisions, from COVID-19 response to long COVID testing and comprehensive health profiles, with a nationwide network of over 2,000 patient service centers for convenient access.[2][4]
Its growth reflects steady expansion, with revenue rising from $7.5 billion in 2018 to a peak of $10.8 billion in 2021 before stabilizing, supported by investments in advanced testing platforms and partnerships with health plans and labs.[1][2]
Quest Diagnostics spun off from Corning Inc. in 1997, evolving from a division focused on clinical laboratory services into an independent powerhouse in diagnostics.[7] Key early milestones include rapid growth through acquisitions and innovation in test development, positioning it as a market leader by the 2000s. The company has since refined its focus under "The Quest Way," integrating purpose (creating a healthier world one life at a time), strategy (enabling better healthcare decisions), and culture (driven by the 5Cs: likely including collaboration, customer focus, and others implied in their operational ethos).[3]
Pivotal moments include its groundbreaking COVID-19 testing response and expansion into direct-to-consumer options like the Elite Health Profile, which measures 85+ health indicators without a doctor's visit, building on decades of clinical expertise.[2][4]
Quest Diagnostics rides the wave of precision medicine and digital health integration, where AI-driven diagnostics, genetic testing, and telehealth demand faster, more accessible lab services amid rising chronic disease prevalence and post-pandemic awareness.[2][3] Timing is ideal as aging populations and value-based care models favor scalable providers like Quest, which influences the ecosystem by standardizing insights for 50% of U.S. hospitals and enabling data-powered decisions that reduce costs and improve outcomes.[1][3] Market forces like regulatory support for direct-to-consumer testing and tech partnerships amplify its role, positioning it as a bridge between labs, providers, and patients in a fragmented $100B+ U.S. diagnostics market.[1][4]
Quest Diagnostics is poised for renewed growth through AI-enhanced testing, expanded consumer health offerings, and global reach, potentially recapturing pre-2022 revenue peaks amid trends like personalized medicine and Long COVID management.[1][2][4] Evolving regulations on direct-access diagnostics and health data interoperability will shape its path, amplifying influence via "The Quest Way" to transform lives at scale. This diagnostic giant, already empowering one in three Americans, stands ready to lead healthcare's data-driven future, tying back to its core mission of actionable insights for a healthier world.[3]
